Syntara Ltd. is a clinical stage drug development company which engages in the development of healthcare products for haematological diseases. Its lead compounds include amsulostat (SNT-5055) and topical pan-LOX inhibitors with SNT-9495. The company was founded by Brett Charlton and William B. Cowden on May 29, 1998 and is headquartered in Sydney, Australia.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
N/A
Frequently Asked Questions
What is Market Cap of Syntara Ltd.?
Market cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares outstanding. Syntara Ltd. market cap is $55.5M.